Nitrianske Pravno, Slovakia

Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus

Development of Atılım Kinesiophobia Scale

Kinesiophobia, or fear of movement, is defined as an excessive and irrational fear of physical movement to avoid painful injury, harm or re-injury. The prevalence of kinesiophobia in chronic painful conditions, especially musculoskeletal pain, has been reported to be between 50% and 70%. Pain-induced fear of movement or kinesiophobia negatively affects response to treatment, recovery and mobility in patients with injury, acute-chronic pain and in patients undergoing rehabilitation. Early and accurate detection of the presence of pain-induced fear of movement and education about kinesiophobia will be beneficial in the rehabilitation and recovery processes of patients (treatment processes will be shortened and recovery success will increase). Today, existing scales measuring kinesiophobia are thought to have some limitations. Especially the Tampa Kinesiophobia Scale is one of the most frequently used scales in the literature to assess kinesiophobia. This scale, whose Turkish validity and reliability study was conducted by the project coordinator and his colleagues, is used by many health professionals working in this field, especially physiotherapists in our country. However, in the studies in the literature and in the previous research of the project coordinator, it was determined that there were limitations and deficiencies related to the scale (the difficulty of patients to understand and answer the questions, the presence of questions that are not suitable for the patient's condition, the lack of questions for patient groups with different characteristics, etc.). For these reasons, it was thought that there was a need to develop a new scale using a simple language that patients could easily understand. The new scale planned to be developed is intended to be able to measure kinesiophobia by including questions for patients with acute, chronic pain, post-surgical pain, neurological and geriatric patients who receive services in the field of physiotherapy and rehabilitation in the clinic. In addition, the scale to be designed is planned to evaluate the patients' fear of movement with biological, psychological and social reasons according to the International Classification of Functioning, Disability and Health (ICF) model. Method: This research is planned as a validity and reliability study in which the Turkish Atılım Kinesiophobia Scale will be developed. After the literature review on the subject, a pool of questions appropriate to the content of the ICF, which evaluates kinesiophobia with patient statements taken from the literature, will be created. Considering the differences in the disease status of the patients, questions for different patient groups mentioned before will be selected and created. The prepared question pool will be presented to the expert opinion of 11 people and the scale questions will be clarified. The pilot study of the scale will be conducted with a total of 40 patients, 10 participants for each patient group. After the pilot study, item analyses and exploratory factor analysis (EFA) analysis will be performed with a sample size of 5 times the number of questions in the item pool with acute and chronic pain patients. Afterwards, confirmatory factor analysis (CFA) analysis will be performed for the factor structure obtained with a sample size 10 times the number of remaining items (a second study). In addition, a correlation analysis study will be performed with the new scale and TSK scale for test-retest reliability (ICC) and validity. , Inclusion criteria: Young, middle-aged, neurologic, geriatric patients aged 18-70 years with chronic musculoskeletal pain problems after acute injury or surgery will be included. Exclusion criteria: illiterate patients, patients with cognitive and cooperation problems will not be included in the study. When the new scale development process is completed, validation studies of the scale on neurological and geriatric patient population will continue. The project outputs are planned to be published as scientific articles within the scope of SCI and as papers in international and national congresses. The project article will be translated into other languages abroad and cultural adaptations will be carried out.

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects with Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy

Auto-Adjustable MOBIDERm Autofit Armsleeve in the Management of Upper Limb Lymphedema.

The overall range of compression devices dedicated to lymphedema treatment offers standard or custom-made garments and different types of bandages. Indeed, bandages are not easy to put on, requiring specific patient's skills and/or assistance which is not optimal for long-term compliance. Moreover, they are composed of several layers forming a quite bulky multilayer bandage that limits limb function and does not contribute to a better quality of life. For all these reasons described, even if bandaging is the current reference of lymphedema treatment, they have disadvantages. The day-time elastic compressive armsleeves are proposed as an alternative to bandages. However, whatever their standard or custom-made design, they cannot adapt to limb volume/morphology evolution on the long-term management of this chronic disease because they are not adjustable. Therefore, as the comfort of treatment is very important in improving compliance, armsleeves are sometimes poorly tolerated by patients resulting in decreasing compliance to treatment plan. In order to optimize treatment of lymphedema efficacy, THUASNE developed the standard Auto-Adjustable Armsleeve using the MOBIDERM technology.

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

This is a three-part open-label, Phase 1/2 clinical trial designed to evaluate the safety, PK, and efficacy of CRB-701 in participants with advanced solid tumors expressing nectin-4. Part A will include solid tumor types known to express nectin-4. Dose escalation will be guided by the Bayesian optimal interval (BOIN) design to determine the MTD of CRB-701. Four (4) dose groups are pre-determined. Dose escalation/de-escalation decisions are made based on the occurrence of DLT. Part B will determine the RP2D of CRB-701 by evaluating two dose levels of CRB-701 by using a time-to-event Bayesian optimal Phase 2 (TOP) study design to optimize the dose of CRB-701 in one or more separate cohorts of participants with nectin-4-positive tumors. During Part C, the RP2D dose of CRB-701 will be evaluated in five planned expansion cohorts using Simon's optimal two-stage design.

Evaluation of the Frequency, Risk Factors, and Outcomes of ROP in Infants with a BW >1500 Grs or GA ≥33 Wks in Turkey.

This study, promoted by the "Turkish Neonatology Society", involved preterm infants who are being screened for ROP between August 1,2023 and August 1, 2024 in level III/IV Turkish NICUs. An electronic questionnaire is being filled by certified neonatologists in Turkey via a special network. Neonatologists working in 94 centers who agreed to participate in this study provide their data regarding the ROP in their NICU. The medical records of retinal examinations of preterm infants who met the screening criteria will be evaluated. A case report form for each patient will be filled including risk factors for the development of ROP such as gestational age, birth weight, small for gestational age (SGA), gender, multiple gestation, antenatal steroid therapy, invitro fertilization, preeclampsia/eclampsia, infants of diabetic mother, chorioamnionitis, resuscitation in delivery room, respiratory distress syndrome (RDS), duration of mechanical ventilation and oxygen therapy, intracranial hemorrhage, hemodynamically significant patent ductus arteriosus (PDA), early/late sepsis, necrotising enterocolitis (NEC), number of blood transfusions, bronchopulmonary dysplasia (BPD), time to full enteral feeding, percentage of own mothers milk. Risk factors for developing ROP will be evaluated. Multivariate analysis will be performed among significant variables. In addition, the incidence of any ROP, severe ROP in relation to GA and BW and treatment modalities will be determined. Severe ROP is defined as ROP requiring treatment. Since Turkey is receiving many refugees in recent years, the investigators also planned to evaluate the incidence and risk factors for developing ROP in preterm babies of refugees. Ophthalmologic examination is continued until full vascularisation. So, the maximum stage of ROP detected for every infant will be reported. Data from 94 NICUs will be pooled together and analyzed. The "International Classification of ROP" guidelines (ICROP-3) are used to record the stage of disease, location by zone, signs of plus disease and signs of regression/reactivation/persistent avascular retina. Criteria for treatment of ROP are based on the Early Treatment for Retinopathy of Prematurity (ETROP) recommendation. Confirmed forms are also assigned by the parents before the initial screening and treatment.

Gait Pattern Analysis After All Arthroscopic ATFL Repair Surgery

Clinical Investigation of Effectiveness of a Calcium Silicate Cement

This clinical study aims to investigate the 18-month clinical performance of calcium silicate and calcium hydroxide materials used in the treatment of deep caries lesions. Material and Methods: Eighty patients who applied to the Restorative Dentistry Clinic of Hacettepe University Faculty of Dentistry, aged between 18-45 years, will be recruited for the study. Patients to be included must have at least one deep dentin caries (D3). For standardization purposes, one researcher will carry out the interventional procedures. Before interventions, any attachments on the teeth will be removed using pumice and polishing rubbers. Restorations will be carried out under rubber dam isolation (OptraDam, Liechtenstein). If the patient experiences any pain, anesthesia will be applied. Dentinal carious lesions will be accessed by the removal of surrounding unsupported enamel with a round diamond bur at high speed under water cooling. Carious tissue in the pulpal aspect of the cavity will be excavated by hand instruments to soft dentin. Only disorganized dentine will be removed. A reasonable amount of soft carious tissue will be left over the pulp. The procedure will be carried out considering the risk of exposing the pulp tissue. In the test group a Calcium silicate, (TheraCal LC, Bisco, Schaumburg, IL, USA), and in the control group a calcium hydroxide (Dycal, Dentsply, Caulk, Milford, DE, USA) materials will be applied to the pulpal floor following the instructions of the manufacturer. Then, these materials in both groups will be sealed by resin-modified glass ionomer cement (SDI, Bayswater, Australia). Selective etching with 37% phosphoric acid (Total Etch-Ivoclar/Vivadent, Liechtenstein) will be applied for 10 s in enamel. Cavities will be rinsed for 10 s, and adhesive material (G-Premio-bond, GC Europe, Leuven, Belgium) will be applied with a micro brush in cavity walls with rubbing for 20 s. After gentle air drying for approximately 5 s, a 1200 W/cm2 intensity LED light device) will be used for 10 s light curing. For the restoration of Class II cavities, a sectional matrix (Palodent V3, Dentsply Sirona, York/Pennsylvania, USA) will be placed. Then, permanent restoration with a posterior composite resin (Gradia Direct Posterior, GC, GC Coop., Tokyo, Japan) will be carried out at the same session. Evaluations will be conducted by two independent researchers after 6, 12, and 18 months according to FDI criteria.

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma